Literature DB >> 35026172

Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models.

Andrea F DiMartini1, Lorenzo Leggio2, Ashwani K Singal3.   

Abstract

Despite its increased recognition as a major public health issue, alcohol use disorder is mostly underdiagnosed and undertreated. The undertreatment and underdiagnosis of alcohol use disorder is most concerning in the management of patients with alcohol-associated liver disease, which is one of the main medical consequences of chronic and excessive alcohol use. Dual pathology (alcohol use disorder and alcohol-associated liver disease) requires multidisciplinary care involving hepatologists and addiction specialists. Such integrated care models are widely accepted as optimal care for treating comorbid medical and mental health conditions. However, the implementation of such models in clinical practice is challenging and often represents the exception, rather than the rule, in managing patients with alcohol use disorder and alcohol-associated liver disease. Barriers at the patient, clinician, and system levels are encountered in treating patients with alcohol use disorder and alcohol-associated liver disease. In this Viewpoint, we synthesise the emerging literature on the potential barriers encountered in caring for patients with alcohol-associated liver disease and alcohol use disorder and focus on how integrated models of care could overcome these barriers. We provide our perspective on why these barriers exist and propose strategies to overcome them.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35026172     DOI: 10.1016/S2468-1253(21)00191-6

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  3 in total

1.  Identifying Alcohol Use Disorder in Patients With Cirrhosis Reduces 30-Days Readmission Rate.

Authors:  Ashwani K Singal; Andrea DiMartini; Lorenzo Leggio; Juan P Arab; Yong-Fang Kuo; Vijay H Shah
Journal:  Alcohol Alcohol       Date:  2022-09-10       Impact factor: 3.913

2.  FGF21 regulates alcohol intake: New hopes on the rise for alcohol use disorder treatment?

Authors:  Tammy Wang; Mehdi Farokhnia; Lorenzo Leggio
Journal:  Cell Rep Med       Date:  2022-03-15

Review 3.  Covid-19 and alcohol associated liver disease.

Authors:  Sasha Deutsch-Link; Brenda Curtis; Ashwani K Singal
Journal:  Dig Liver Dis       Date:  2022-08-03       Impact factor: 5.165

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.